ResMed (NYSE: RMD, ASX: RMD) announced that Carol Burt will become Lead Director on November 15, 2026, succeeding Ron Taylor, who will retire after more than 21 years of service on the company's board.

Burt has served on ResMed's board since 2013 and currently chairs the Nominating and Governance Committee. She also serves on the Audit Committee and the Compliance, Privacy and Quality Committee. Her appointment as Lead Director takes effect three days before ResMed's 2026 Annual Meeting of Stockholders, scheduled for November 18, 2026.

Taylor joined ResMed's board in 2005 and has served as Lead Director since 2013. He will not stand for reelection at the upcoming annual meeting.

"Carol is an outstanding leader with deep governance experience, broad healthcare industry knowledge and a strong commitment to ResMed's mission," said Mick Farrell, ResMed's Chairman and CEO. "I look forward to continuing to work closely with Carol and the entire Board as we advance our strategy and create long-term value for our shareholders."

Farrell also commented on Taylor's departure: "Ron has made extraordinary contributions to ResMed over the past two decades. His integrity, sound judgment and unwavering commitment to our patients, employees and shareholders have helped shape ResMed."